医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mystic Pharmaceuticals Receives Notices of Allowance from Japan and China on Drug Delivery Platform Technologies

2013年10月01日 PM07:25
このエントリーをはてなブックマークに追加


 

AUSTIN, Texas

Mystic Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, announced today it has received Notices of Allowance from the China Patent Office for its “Deep Draw Container Forming Method” (invention number ZL200880106965.1) and the Japan Patent Office for its “Combination Unit Dose Dispensing Container” (application number 2010-508588) patent applications. Mystic’s VersiDoser® and VRx2™ delivery technologies are used in combination with drugs and biologics to develop therapeutics for the treatment of ocular, CNS, neurodegenerative and infectious diseases affecting large global populations.

Timothy Sullivan, Mystic’s President and CEO, stated that, “Over the past decade Mystic has innovated packaging and delivery technologies that enable the development of patient-centric pharmaceutical products. Japan and China along with several other global markets are high priority strategic opportunities for Mystic enhanced pharmaceutical drug/device combined products. These latest international patents reflect our long term commitment to developing the global market opportunity for our technology and products.” Mystic’s VersiDoser® and VRx2™ delivery platforms utilize novel unit dose packaging and patient-centric dispensers that can be configured for precision self-administration of therapeutics for ophthalmic, systemic nasal, nose to brain, sublingual, oral and dermal applications.

Mystic’s delivery platform technologies enable pharmaceutical and biotech manufacturers to develop patient-oriented products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics. The shift to patient-centric products benefits the consumer through improved compliance and health outcomes while building brand value for the pharmaceutical manufacturer. Mystic’s delivery platforms and products are designed to meet the diverse demands of consumers and pharma manufacturers in the globally competitive market.

About Mystic Pharmaceuticals, Inc.

Mystic Pharmaceuticals™ is an integrated specialty pharmaceutical company based in Austin, Texas. Mystic provides patient-centric pharmaceutical products and delivery technology and for pharmaceuticals, biopharmaceuticals and biologics for intranasal, ophthalmic, sublingual, dermal and otic applications. Mystic combines its novel delivery systems with pharmaceuticals and biologics under development by Mystic and its partners, to meet the expanding global market demand for healthcare products that are safer, simpler to use and cost effective. For more information please visit the Mystic website: www.mysticpharmaceuticals.com.

CONTACT

Mystic Pharmaceuticals, Inc.
Melissa Brandt, +1-512-918-2900 ext.
224
mbrandt@mysticpharmaceuticals.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田呈报3期ALTA-1L试验结果,显示在晚期ALK+非小细胞肺癌一线治疗中,ALUNBRIG® (brigatinib)的颅内有效性优于克唑替尼
  • Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product
  • PotNetwork Holdings, Inc.第三季度业绩创纪录,营收超过610万美元
  • ポットネットワーク・ホールディングスが610万ドルを超える収益で過去最高の第3四半期を終える
  • ポットネットワーク・ホールディングスがSEC報告会社となるためにフォーム10を提出